RxDoctor Payments Data

James Freeman, DO

Internal Medicine · Macungie, PANPI 1417903790

Payments from drug & device makers

$406in general payments, 2019–2025

Across 15 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$167
  • Amarin Pharma, Inc.$125
  • AstraZeneca$27
  • Biohaven Pharmaceutical Holding Company Ltd.$22
  • Alcon$19
  • Lilly USA, LLC$18
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$36289%
  • Education$4411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$80,826
Medicare patients
197
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$67,998
JardianceEmpagliflozin26$38,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$29,657
XareltoRivaroxaban20$25,321
OzempicSemaglutide19$25,135
FarxigaDapagliflozin Propanediol19$17,600
JanumetSitagliptin Phos/Metformin Hcl11$16,555
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,936
Valsartan78$2,796
Temazepam11$2,556
Levothyroxine Sodium197$1,816
Gabapentin88$1,808
Tamsulosin Hcl96$1,773
Omeprazole182$1,699
Atorvastatin Calcium212$1,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$15$29,65733 claims
Novo NordiskOzempic$167$25,13519 claims
AstraZenecaFarxiga$27$17,60019 claims
AbbVieSynthroid$13$1,24133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Macungie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →